More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.

Verheijen, S; van Luin, M; Brüggemann, R J; de Mast, Q; Hassing, R J; Burger, D M

Verheijen, S; van Luin, M; Brüggemann, R J; de Mast, Q; Hassing, R J; Burger, D M.

Verheijen S; Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: shenna.verheijen@student.ru.nl.
van Luin M; Rijnstate Hospital, Arnhem, The Netherlands.
Brüggemann RJ; Radboud University Medical Center, Nijmegen, The Netherlands.
de Mast Q; Radboud University Medical Center, Nijmegen, The Netherlands.
Hassing RJ; Rijnstate Hospital, Arnhem, The Netherlands.
Burger DM; Radboud University Medical Center, Nijmegen, The Netherlands.

Int J Infect Dis ; 103: 402-403, 2021 02.

Article in English | MEDLINE | ID: covidwho-1019098

Subject(s)

COVID-19 Drug Treatment; Hydroxychloroquine; Chloroquine/adverse effects; Humans; Hydroxychloroquine/adverse effects; Intensive Care Units; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google